SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.
$BBOT
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/17/2025 | $25.00 | Outperform | Leerink Partners |
| 9/15/2025 | $27.00 | Buy | H.C. Wainwright |
| 8/15/2025 | $21.00 | Overweight | Piper Sandler |
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September. Details of the company's participation are as follows: Cantor Global Healthcare Conference Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York Morgan Stanley Global Healthcare Conference Fireside Chat: Monday, September 8 at 7:45 a.m. ET as well as hosting investor meetings in New York Links for live webcasts and replays, if
EFFECT - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
Leerink Partners initiated coverage of BridgeBio Oncology Therapeutics with a rating of Outperform and set a new price target of $25.00
H.C. Wainwright initiated coverage of BridgeBio Oncology Therapeutics with a rating of Buy and set a new price target of $27.00
Piper Sandler initiated coverage of BridgeBio Oncology Therapeutics with a rating of Overweight and set a new price target of $21.00